Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1598

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 9C
Chunk 1598
---
 These expenses are regularly reviewed by the CODM as a single category for internal
  decision-making purposes.

  2
  General and administrative expense includes overhead, clinical trial-related administrative and planning costs, and manufacturing-related
costs such as raw materials. These are not separately reviewed by the CODM and are assessed as part of the broader G&A category for
decision-making purposes.

  3
  Cash used in operating activities is a key metric monitored by the CODM in evaluating resource needs, development pacing, and investment
feasibility in the absence of revenue.

     F-25 

The Company does not allocate assets by segment, and the CODM does
not use a measure of segment profit or loss to evaluate performance. There were no changes to the internal reports provided to or reviewed
by the CODM during the years presented.

Entity-Wide Information:

·The
Company did not recognize revenue during the fiscal year ended March 31, 2025.
·All
long-lived assets are located in the United States.
·A
significant portion of clinical trial activity is conducted through the Company’s wholly owned subsidiary based in Australia.

10. SUBSEQUENT EVENTS

On June 25, 2025, the Company
received notice from Nasdaq stating the Company has regained compliance with Listing Rule 5550(a)(2), and that the matter is now
closed.

Reverse
Split – Following the approval of a reverse stock split at a Special Meeting of Stockholders on May 13, 2025, our Board of Directors
approved a 1-for-8 reverse stock split or our outstanding shares of Common Stock, effective as of the close of business on June 6, 2025
with an effective trading date of June 9, 2025. Accordingly, each 8 shares of outstanding common stock held by stockholders were combined
into one share of common stock. Our authorized common stock remained at 60,000,000 shares following the stock split. We issued an additional
77 shares as a result of rounding up fractional shares related to the reverse stock split.

On
June 2 and June 16, 2025, the second and third patients, respectively, were treated with the Aethlon Hemopurifier at GenesisCare North
Shore in Sydney, Australia. Each patient underwent a single 4-hour treatment session and tolerated the procedure without complications.
Follow-up visits will include safety assessments, extracellular vesicle (EV) and T cell measurements, as well